Rimonabant (Acomplia), discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia and under the name as Zimulti in USA.

How Acomplia/Rimonabant/Zimulti Works?

Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable.

In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.

Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.

How can I buy Rimonabant/Acomplia/Zimulti ?

Acomplia Rimonabant has been approved as a new weight loss drug in a lot of European countries. It is available in many European countries and can be bought online by the consumers from US.

Buying Rimonabant Acomplia helps you to treat obesity but this new class weight loss drug Rimonabant Acomplia is not yet approved for smoking cessation. It is still waiting for the approval from European union for smoking cessation.